News ArticleSai Life Sciences Appoints Three Senior Vice Presidents and Reports Q2 FY2026 Financial Results with Equity Capital Rise
Board approves appointments effective 5 November 2026 and equity share capital increases to ₹21,25,80,721 after ESOP allotments; unaudited results for September 2026 quarter released
Sai Life Sciences announced the appointment of three senior management personnel including the Senior Vice President of HR, Vice President of Quality & Regulatory Affairs, and Senior Vice President of Corporate Communications effective 5 November 2026. The company also approved its unaudited standalone and consolidated financial results for Q2 and H1 ended 30 September 2026, and increased its equity share capital from ₹21,24,72,716 to ₹21,25,80,721 following allotment of shares under ESOP 2008 and MESOP 2018.
Sai Life Sciences Limited
General / Other
Sai Life Sciences Limited has appointed three senior vice presidents across Human Resources, Quality & Regulatory Affairs, and Corporate Communications, while also releasing its unaudited financial results for the quarter and half-year ended September 30, 2026. The company's equity share capital has increased following share allotment under employee stock option plans.
The Board of Directors approved the unaudited standalone and consolidated results for the second quarter and half-year period ending 30th September 2026.
Senior management appointments effective 5th November 2026 include Mr. Sidhartha Das as Senior Vice President & Head - Human Resources, Mr. Vijay Kumar Suthari as Vice President - Head Quality & Regulatory Affairs, and Mr. Sriram Gopalakrishnan as Senior Vice President - Corporate Communications.
Mr. Das brings over 25 years of cross-sector HR experience including FMCG and Life Sciences, with expertise in talent management and organizational growth.
Mr. Suthari brings extensive 24 years’ experience in pharmaceutical quality assurance, regulatory compliance, and quality systems from leading companies like Dr. Reddy’s Laboratories and Pfizer India Limited.
Mr. Gopalakrishnan has over 25 years in marketing and communications, strengthening Sai Life Sciences’ brand since 2018, with prior roles at Dr. Reddy’s Laboratories and the Indian School of Business (ISB).
Highlights
- 27,005 and 81,000 equity shares allotted upon exercise of stock options under ESOP 2008 and MESOP 2018 respectively.
- Issued equity share capital increased from ₹21,24,72,716 to ₹21,25,80,721.
- Board meeting held on 5th November 2026 from 9:20 PM to 9:42 PM IST.
- Limited review reports accompany the unaudited financial results.
- Appointments made based on Nomination and Remuneration Committee recommendation.
Key Data Snapshot
What happened
- Sai Life Sciences approved unaudited standalone and consolidated financial results for Q2 and half-year ended 30 September 2026.
- Board appointed three senior management personnel effective 5 November 2026, including heads for HR, Quality & Regulatory Affairs, and Corporate Communications.
- The company allotted 27,005 and 81,000 equity shares under ESOP 2008 and MESOP 2018 respectively, increasing equity share capital.
Key details
- Mr. Sidhartha Das appointed as Senior Vice President & Head - Human Resources with 25+ years experience.
- Mr. Vijay Kumar Suthari appointed as Vice President - Head Quality & Regulatory Affairs with 24+ years in pharmaceutical quality and regulatory roles.
- Mr. Sriram Gopalakrishnan appointed as Senior Vice President - Corporate Communications, with 25+ years marketing and communications experience.
Background and context
- ESOP 2008 and MESOP 2018 are employee stock option plans under which shares were allotted.
- Appointment decisions were made following recommendations from the Nomination and Remuneration Committee.
- The financial results are accompanied by limited review reports as required by regulations.
Highlights
- 27,005 and 81,000 equity shares allotted upon exercise of stock options under ESOP 2008 and MESOP 2018 respectively.
- Issued equity share capital increased from ₹21,24,72,716 to ₹21,25,80,721.
- Board meeting held on 5th November 2026 from 9:20 PM to 9:42 PM IST.
- Limited review reports accompany the unaudited financial results.
- Appointments made based on Nomination and Remuneration Committee recommendation.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- SEBI Master Circular No. HO/49/14/14(7)2025 -CFD -POD2/I/3762/2026 dated 30th January 2026
- SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Sansera Engineering Achieves Record INR 10,915 Million Quarterly Revenue and 59% Normalised PAT Growth in Q2 FY27
Sansera Engineering Limited reported its highest-ever quarterly revenue of INR 10,915 million for Q2 FY27, a 32% increase year-over-year, alongside a normalized profit after tax of INR 1,000 million, up 59% YoY excluding an exceptional litigation-related cost.
Read Full Story
Godfrey Phillips India Declares ₹10 Interim Dividend and Posts ₹16,298 Lakh Profit for Q2 FY2027
Godfrey Phillips India Limited declared an interim dividend of 500% or ₹10 per equity share for the financial year ending March 31, 2027, while reporting an unaudited standalone net profit of ₹16,298 lakh for the quarter ended September 30, 2026.
Read Full Story
IKS Health Doubles Revenue with 103.9% YoY Growth and Boosts EBITDA by 62.5% in Q2 FY27 Post TruBridge Deal
Inventurus Knowledge Solutions Limited (IKS Health) announced strong Q2 FY27 financial results with revenue surpassing INR 15,900 million, marking a 103.9% year-on-year increase supported by its TruBridge acquisition and sustained organic growth.
Read Full Story
